Core Insights - The article discusses how Shijiazhuang, an old industrial city in Hebei Province, is transforming its economy by focusing on high-quality industrial development and creating five major industrial clusters worth over 100 billion yuan each [1][3]. Industrial Development - Shijiazhuang is revitalizing its economy by optimizing traditional industries, strengthening emerging sectors, and planning for future industries, with a focus on biomedicine, new-generation electronic information, advanced equipment manufacturing, modern food, and modern commercial logistics [1][3]. - The city has established a systematic approach to promote the five major industrial clusters, emphasizing policy guidance, technological innovation, and project construction [3][4]. Electronic Information Industry - The Luquan Economic Development Zone in Shijiazhuang has become a hub for the electronic information industry, hosting major companies and research institutes, and forming six advantageous industrial chains in semiconductor chips, modern communication, and more [2][4]. - The electronic information sector has seen significant growth, with revenue projected to increase from 771.7 billion yuan in 2021 to 1,381.7 billion yuan by 2024, reflecting an annual growth rate of 12.1% [5]. Biomedicine Sector - Shijiazhuang is recognized as a "Pharmaceutical Capital," with major companies like Shijiazhuang Pharmaceutical Group leading the industry. However, challenges remain in core technology and high-end talent acquisition [2][5]. - The biomedicine industry is expected to grow from 771 billion yuan in 2021 to 1,257.2 billion yuan by 2024, with an annual growth rate of 10.8% [5]. Innovation and R&D - The city has invested heavily in R&D, with a budget of 211.6 billion yuan for 2024, aiming to enhance technological innovation and industry integration [6][8]. - Shijiazhuang has established numerous partnerships with universities and research institutions to foster innovation, resulting in over 400 cooperation agreements and the establishment of multiple innovation platforms [7][8]. Talent Development - The city has implemented a talent strategy that includes various incentives and support measures, attracting over 10,000 young talents in 2024 alone [12][15]. - Shijiazhuang has created a favorable environment for talent retention, including housing support and financial incentives, contributing to its recognition as a top city for talent attraction [13][15]. Business Environment - Shijiazhuang is focused on creating a market-oriented, law-based, and international business environment, streamlining administrative processes and enhancing service efficiency for enterprises [9][10]. - The city has introduced measures to protect intellectual property rights, which are crucial for fostering innovation and ensuring fair competition [11].

致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 本月底法定/ ...

Core Viewpoint - Shenwei Pharmaceutical (02877) reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a year-on-year decrease of 16.3% [1] Revenue Breakdown - The revenue from injection products decreased by 23.6% to RMB 786 million [1] - The revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - The revenue from granule products decreased by 14.5% to RMB 391 million [1] - The revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - The revenue from other dosage forms decreased by 6.1% to RMB 175 million [1]

Core Viewpoint - The company reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a 16.3% decrease compared to the same period in 2024 [1] Revenue Breakdown - Revenue from injection products decreased by 23.6% to RMB 786 million [1] - Revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - Revenue from granule products decreased by 14.5% to RMB 391 million [1] - Revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - Revenue from other dosage forms decreased by 6.1% to RMB 175 million [1] Product Contribution to Total Revenue - Injection products accounted for approximately 32.5% of total revenue [1] - Soft capsule products accounted for approximately 14.0% of total revenue [1] - Granule products accounted for approximately 16.2% of total revenue [1] - Traditional Chinese medicine formula granules accounted for approximately 30.1% of total revenue [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示，概不會就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED 中國神威藥業集團有限公司 中國神威藥業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2877 （股份代號：2877） 中國神威藥業集團有限公司（「本公司」）董事會（「董事會」）欣然公告，本公司及其附屬公司（統 稱「本集團」）截至二零二五年九月三十日止九個月未經核數師審閱的管理賬目內營業額為人民幣24.15 億元，較二零二四年同期減少16.3%，分別是： 以產品劑型分析，截至二零二五年九月三十日止九個月，注射液產品、軟膠囊產品、顆粒劑產品及中藥 配方顆粒產品分別佔本集團之營業總額約32.5%、14.0%、16.2%及30.1%。 股 東 及 投 資 者 於 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事 。 股 東 及 投 資 者 於 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承 ...

截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2025年10月31日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定 ...

Core Viewpoint - Shenwei Pharmaceutical Group has received approval for its self-developed Shengxian Decoction Granules, marking its fourth classic prescription approval and the first of its kind in Hebei Province [1] Group 1: Product Development - Shengxian Decoction Granules are based on a prescription from the Qing Dynasty physician Zhang Xichun, consisting of five medicinal ingredients: Astragalus, Anemarrhena, Bupleurum, Platycodon, and Cimicifuga, aimed at treating symptoms of "Qi deficiency" such as shortness of breath and fatigue [1] - The company has established a comprehensive R&D system since 2017, focusing on classic prescriptions, which includes ancient text research, medicinal material tracing, process innovation, and clinical validation [1] Group 2: Market Position - Shenwei Pharmaceutical Group is one of the earliest companies in China to conduct research on classic prescriptions and holds one of the highest numbers of classic prescription projects [1] - The company has over 100 classic prescriptions and innovative traditional Chinese medicine projects under development, covering various therapeutic areas including respiratory, digestive, and gynecological systems, with several products already in the application stage [1]

Group 1 - The Hebei Provincial Drug Administration conducted GAP (Good Agricultural Practices) extension inspections on several traditional Chinese medicine (TCM) cultivation bases, confirming compliance with quality management standards [2] - The inspected companies include Shenwei Pharmaceutical Group, Anguo Shengshan Pharmaceutical Co., and Shijiazhuang Yiling Pharmaceutical Co., with all results meeting the required standards [2] - The inspection results are part of the implementation of the national quality management guidelines for TCM production, aimed at ensuring the quality and safety of herbal medicines [2] Group 2 - Shenwei Pharmaceutical Group's cultivation bases for Chuanxiong and related products were evaluated, with a total area of 650 acres across two locations in Sichuan Province [2] - Shijiazhuang Yiling Pharmaceutical Co. has a gold flower cultivation base covering 1,100 acres in Hebei Province, which also passed the inspection [2] - Anguo Shengshan Pharmaceutical Co. operates a half summer cultivation base of 1,185 acres, with multiple plots also meeting the compliance requirements [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000 ...

19 September 2025 Dear non-registered shareholder(s), China Shineway Pharmaceutical Group Limited (the "Company") – Notification of Publication of 2025 Interim Report (the "2025 Interim Report") We hereby notify you that the English and Chinese versions of the 2025 Interim Report are now available on the Company's website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk. (Incorporated in the Cayman Islands with limited liability) （在開曼群島註冊成立之有限公司） （Stock Code 股份代號：2877） NOTIFICATION LETT ...